Micromachines (Basel). 2021;12(2):mi12020215.

Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology.

, , , , ,

제1저자 황성혜 · 교신저자 김세중

PMID 33669950 PMC7924856 DOI 10.3390/mi12020215 IF 3.5 신장내과

소속 (5)

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea.
Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea.
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.
Department of Mechanical Engineering, KAIST, Daejeon 34141, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.

Abstract

Organ-on-a-chip (OoC) is an exponential technology with the potential to revolutionize disease, toxicology research, and drug discovery. Recent advances in OoC could be utilized for drug screening in disease models to evaluate the efficacy of new therapies and support new tools for the understanding of disease mechanisms. Rigorous validation of this technology is required to determine whether OoC models may represent human-relevant physiology and predict clinical outcomes in target disease models. Achievements in the OoC field could reveal exciting new avenues for drug development and discovery. This review attempts to highlight the benefits of OoC as per our understanding of the cellular and molecular pathways in lung and kidney cancer models, and discusses the challenges in evaluating drug efficacy.

Keywords

cancer modelsdrug efficacydrug testingmicrofluidics technologiesorgan-on-a-chip

Figures

**Figure 1** Organ-on-a-chip models for mimicking a single organ or a combination of organs. (a) Kidney-on-a-chip is developed for monitoring nephrotoxicity. Schematic design and actual image of a kidney-on-a-chip. Junctional protein expression of each group. The static and shear groups are measured before exposure to gentamicin, and D1 and D2 groups are measured 24 h after exposure to gentamicin. All groups show improved polarization compared to Transwell cultures. Source: *Biofabrication,* 2016 [56]; (b) lung/liver-on-a-chip combines two types of organs for investigating aerosol toxicity. A photograph of the chip system comprising the pump main unit with four pump heads, the PEEK chip, and the reservoir plate. A schematic view of the chip comprising four circuits is shown; each circuit includes two compartments to house the lung and liver tissues. The cross-section schemas of the plates show the path of the tubes and channels and the relative depth of each well. Source: *Lab Chip,* 2018 [55]; (c) a close-up view of the two compartments showing the groove pattern on the bottom of the wells; left (c). AFB1 toxicity was assessed using the lung/liver-on-a-chip. TEER and ATP content were measured in untreated or AFB1-exposed NHBE ALI tissues either in monoculture (NHBE ALI, dynamic) or coculture with HepaRG spheroids (NHBE ALI, coculture); right (c) nanofiber-membrane-assisted lung-on-a-chip system is used for anticancer drug testing. Source: *Lab Chip,* 2018 [54].

그림 출처: PubMed Central 공개 논문 (PMC7924856)

Conflict of interest statement

The authors declare no conflict of interest.

그 밖의 정보